Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Thyroid test revolution: new study seeks better way to monitor hormone levels

NCT ID NCT06083636

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether measuring a different thyroid hormone (fT3) or the ratio of two hormones (fT3/fT4) can give a clearer picture of thyroid health in people taking levothyroxine. It includes 500 adults with various types of hypothyroidism who are on a stable dose of the medication. The goal is to improve lab tests for patients where the usual TSH test isn't reliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with hypothyroidism using levothyroxine (L-T4) attending the outpatient clinic of Amsterdam UMC will be included. Healthy euthyroid controls will be recruited amongst employees of Amsterdam UMC.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: In order to be eligible to participate in this study, a hypothyroid subject must meet all of the following criteria: * Ability to provide informed consent * Ability to speak and understand Dutch or English * Intake of a stable dosage of levothyroxine, meaning the dosage of levothyroxine must not be changed during the appointment at the outpatient clinic * Diagnosis of one these forms of hypothyroidism * Patients with primary hypothyroidism: euthyroid based on TSH according to physician * Patients with hypothyroidism after a total thyroidectomy due to thyroid carcinoma (therefore athyroid): on target TSH according to physician (target TSH depending on stage/severity of carcinoma) * Patients using L-T4 due to therapy of Graves' disease: euthyroid based on TSH according to physician (TSH cannot be suppressed, namely TSH within reference interval of 0,5-5,0 mU/L) * Patients with central hypothyroidism: euthyroid based on fT4 according to physician (common is fT4 in the upper limit, reference interval is 12-22 pmol/L) In order to be eligible to participate in this study, a healthy control subject must meet all of the following criteria: * Ability to provide informed consent; * Ability to speak and understand Dutch or English * Consider themselves healthy Exclusion Criteria: A potential hypothyroid subject who meets any of the following criteria will be excluded from participation in this study: * Not euthyroid according to physician * Pregnancy * Patients using L-T4 due to therapy of Graves' disease: if TSH is still suppressed * Any of the following medication * Liothyronine (Cytomel) * Iodide * Oral contraceptives * Active treatment of malignancy (other than thyroid carcinoma) A potential healthy control subject who meets any of the following criteria will be excluded from participation in this study: * Pregnancy * Any of the following medication * Thyroid medication (a.o. levothyroxine, thiamazol, PTU) * Lithium * Amiodarone * Propranolol * Iodide * Glucocorticoids * Oral contraceptives * Heparin * Growth hormone * Active treatment of malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central hypothyroidism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.